Stay updated on Oral QLT091001 in LCA/RP Due to RPE65/LRAT Mutations Clinical Trial
Sign up to get notified when there's something new on the Oral QLT091001 in LCA/RP Due to RPE65/LRAT Mutations Clinical Trial page.

Latest updates to the Oral QLT091001 in LCA/RP Due to RPE65/LRAT Mutations Clinical Trial page
- Check5 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed study information regarding the evaluation of QLT091001 for Leber Congenital Amaurosis (LCA) and Retinitis Pigmentosa (RP), while retaining the mention of LCA and a new revision number.SummaryDifference16%
- Check41 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check85 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check99 days agoChange DetectedThe webpage now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check107 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
Stay in the know with updates to Oral QLT091001 in LCA/RP Due to RPE65/LRAT Mutations Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Oral QLT091001 in LCA/RP Due to RPE65/LRAT Mutations Clinical Trial page.